Mycenax Biotech Inc. (TPEX: 4726)

Market Cap	9.41B
Revenue (ttm)	672.85M
Net Income (ttm)	-536.33M
Shares Out	206.11M
EPS (ttm)	-2.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	309,291
Open	46.95
Previous Close	46.50
Day's Range	45.75 - 47.00
52-Week Range	34.90 - 65.20
Beta	1.06
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About Mycenax Biotech

Mycenax Biotech Inc. develops and manufactures biopharmaceutical products from mammalian and microbial cell lines in Taiwan, Europe, Asia, and the United States. The company develops monoclonal antibodies, bi-specific antibodies, fc-fusion proteins, recombinant proteins, peptides, protein conjugates (non-toxin), antibody-cell conjugates, enzymes, antigen-binding fragments (Fab), and single-chain variable fragments (ScFv), as well as plasmids and DNA vaccines. It also provides process development solutions, including development of production ce...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 387
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4726

Financial Performance

In 2023, Mycenax Biotech's revenue was 652.62 million, a decrease of -10.88% compared to the previous year's 732.28 million. Losses were -682.85 million, 50.5% more than in 2022.